NGAL and cystatin-C level were measured on arrival to the cathlab prior to primary PCI in 701 STEMI patients and were correlated to the occurrence of CI-AKI according to the various existing definitions. Association between biomarkers level and the incidence of CI-AKI, MACE and allcause mortality at 1-year-follow-up were evaluated. Biomarkers were added to clinical data into a multivariate model analysis to evaluate their additive diagnosis and prognosis value.
Incidence of AKI varied from 12.0% to 21.5% depending of the definition. When divided in tertiles, levels of plasmatic NGAL and cystatin C were associated with a stepwise increase in the incidence of AKI and the stage of renal failure. Both biomarkers significantly predicted CI-AKI with receiver operating characteristic (ROC) analysis showing an area under curve of 0.60 for cystatin C, and 0.62 for NGAL, both p < 0.05.
MACCE and all-cause mortality at 1-year-follow-up were also higher in the higher tertile for both biomarkers (p value <0.01) (see figure).
In myocardial infarction, NGAL and cystatin C are correlated with the incidence and severity of AKI, and occurrence of MACCE and all cause mortality at one year.
The author hereby declares no conflict of interest